Eastman Chemical Company EMN
Composite 46/100; the shares have moved about 32% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 13/100 — a strong mark against it.
Income ranks 86/100 — a strong point in its favour. Valuation ranks 69/100 — a moderate point in its favour.
Growth ranks 13/100 — a strong mark against it. Quality ranks 37/100 — a moderate mark against it. Momentum ranks 45/100 — a slight mark against it.
What the company does Eastman Chemical (EMN) is a specialty materials and chemicals company serving markets like transportation, electronics, agriculture, and construction. Its segments include Additives & Functional Products, Advanced Materials, and Chemical Intermediates, providing niche polymers, solvents, and intermediates.
Key financials EMN’s profitability metrics are weak: ROE 7%, ROA 4%, ROCE 5%, with net margin 5%. Revenue and EPS fell -5% and -41% YoY. Debt/Equity is 0.90, net debt/EBITDA 3.49, and interest coverage is 3.12. Dividend yield is 5% but payout ratio is 97%.
Stock health Technical momentum is mixed: 12m -3%, RSI 55, and -14% from the 52-week high. Sideravia scores valuation at 71st percentile but quality at 29th, flagging poor fundamentals despite attractive valuation.
Price vs fair value The stock trades at a PREMIUM of 86% to our fair-value estimate and a discount of 16% to the analyst 12-month target. - Q2 earnings beat and revenue growth cited as near-term tailwinds (Zacks 2026-07-31) - Analysts highlight volume growth and pricing power supporting estimates (Zacks 2026-07-30) - Weak peer results (MEOH) may be lifting sentiment for EMN (Zacks 2026-07-28)
Looking forward Forward P/E of 11x and PEG of 0.12 suggest valuation support, but weak fundamentals and high payout strain capacity. Analysts see 15% upside to $81 over 12 months, balancing near-term positives against structural headwinds.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.